The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
NCT ID: NCT07314255
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
60 participants
OBSERVATIONAL
2025-12-18
2027-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Inclusion criteria:
1. History of total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma (PTC);
2. At least one course of \^131I internal radiotherapy.
Exclusion criteria:
1. Presence of other severe comorbidities;
2. Incomplete clinical or follow-up data. The clinicopathological characteristics and Trop2 expression levels in tissue samples were compared between the \^131I treatment-responsive group and the \^131I treatment-resistant group.
Within the \^131I treatment-resistant group, comparisons were made between the rapidly progressing subgroup and the stable-disease subgroup under TSH-suppressive therapy in terms of clinicopathological features, tissue Trop2 expression levels, and SUVmax of metastatic lesions on \^18F-Trop2 PET-CT imaging. Factors influencing progression-free survival and overall survival in \^131I-resistant patients were analyzed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
NCT01413113
Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer
NCT06362772
Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
NCT06134830
Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
NCT02773667
Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry
NCT05299437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RAI responder
The ¹³¹I treatment-responsive group was defined as patients who achieved successful radioactive iodine therapy (i.e., lesions disappeared or showed no long-term progression after radioiodine uptake).
radioiodine-131 therapy
surgery, tsh inhibition therapy
RAI nonresponder
The ¹³¹I treatment-resistant group was defined as patients meeting any of the following criteria:
No radioiodine uptake in metastatic tissues during the first ¹³¹I treatment, with insignificant decrease or an increase in serum Tg levels before and after therapy; Partial lesions exhibit radioiodine uptake while others showed no uptaking; Progressive metastatic disease despite evident radioiodine uptake.
radioiodine-131 therapy
surgery, tsh inhibition therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
radioiodine-131 therapy
surgery, tsh inhibition therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lin Zhou
UNKNOWN
Zhijun Chen
UNKNOWN
Yu Su
UNKNOWN
Jingxiu Zhong
UNKNOWN
Tianzhu Lu
UNKNOWN
Jiangxi Provincial Cancer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
lin zhou
Role: PRINCIPAL_INVESTIGATOR
Jiangxi Provincial Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202211013
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Trop2 and PTC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.